ISEE IVERIC bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ISEE

Price (delayed)

$38.03

Market cap

$5.24B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.77

Enterprise value

$4.87B

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing ...

Highlights
The equity has increased by 43% YoY but it has decreased by 11% from the previous quarter
IVERIC bio's net income has plunged by 82% YoY and by 20% from the previous quarter
ISEE's EPS has dropped by 58% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ivericbio.com
Peers: OVID

Key stats

What are the main financial stats of ISEE
Market
Shares outstanding
137.78M
Market cap
$5.24B
Enterprise value
$4.87B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.93
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$222.9M
EBITDA
-$222.72M
Free cash flow
-$177.21M
Per share
EPS
-$1.77
Free cash flow per share
-$1.29
Book value per share
$3.48
Revenue per share
$0
TBVPS
$4.47
Balance sheet
Total assets
$613.41M
Total liabilities
$136.36M
Debt
$97.76M
Equity
$477.05M
Working capital
$572.17M
Liquidity
Debt to equity
0.2
Current ratio
15.53
Quick ratio
15.24
Net debt/EBITDA
1.66
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-46.2%
Return on equity
-57%
Return on invested capital
-109.5%
Return on capital employed
-38.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ISEE stock price

How has the IVERIC bio stock price performed over time
Intraday
0.64%
1 week
0.72%
1 month
0.82%
1 year
264.27%
YTD
77.63%
QTD
56.31%

Financial performance

How have IVERIC bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$229.08M
Net income
-$222.9M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 87% YoY and by 21% from the previous quarter
IVERIC bio's net income has plunged by 82% YoY and by 20% from the previous quarter

Growth

What is IVERIC bio's growth rate over time

Valuation

What is IVERIC bio stock price valuation
P/E
N/A
P/B
10.93
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ISEE's EPS has dropped by 58% year-on-year and by 16% since the previous quarter
The stock's price to book (P/B) is 160% more than its 5-year quarterly average of 4.2 and 82% more than its last 4 quarters average of 6.0
The equity has increased by 43% YoY but it has decreased by 11% from the previous quarter

Efficiency

How efficient is IVERIC bio business performance
ISEE's return on equity is down by 24% year-on-year and by 9% since the previous quarter
The ROIC has grown by 14% year-on-year but it has declined by 11% since the previous quarter
ISEE's return on assets is down by 9% year-on-year and by 4.3% since the previous quarter

Dividends

What is ISEE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ISEE.

Financial health

How did IVERIC bio financials performed over time
The total assets has surged by 74% year-on-year but it has declined by 8% since the previous quarter
ISEE's current ratio is down by 17% since the previous quarter and by 15% year-on-year
The debt is 80% smaller than the equity
The equity has increased by 43% YoY but it has decreased by 11% from the previous quarter
ISEE's debt to equity is up by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.